Jeffrey E. Rubnitz - Concepedia

Author

Jeffrey E. Rubnitz

St. Jude Children's Research Hospital ORCID

Also Known As

Ching-Hon Pui, Daisuke Tomizawa, J E Rubnitz, J Rubnitz, J. E. Rubnitz, J. Rubnitz, J.E. Rubnitz, JE Rubnitz, Janke Lj, Jeffery E. Rubnitz

555

Publications

27.7K

Citations

H-Index

103

Concepts

All Affiliations

St. Jude Children's Research Hospital University of Tennessee Health Science Center National University of Singapore Stanford University Erasmus MC - Sophia Children’s Hospital

About

Jeffrey E. Rubnitz is an author at St. Jude Children's Research Hospital specializing in medicine, hematology, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	71	9.5K
2	Health Sciences	17	20	1.8K
3	Natural Sciences	7	7	613
4	Public Health	2	2	228
5	Blood Transplantation	2	2	684

Jeffrey E. Rubnitz

211

Publications

25K

Citations

H-Index

Page 1

	Year	Citations
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation Ching-Hon Pui, Dario Campana, Deqing Pei, New England Journal of Medicine	2009	1.2K
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia Elaine Coustan‐Smith, Charles G. Mullighan, Mihaela Onciu, The Lancet Oncology Hematological MalignancyMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematologyImmunology	2009	999
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial Rob Pieters, Martin Schrappe, Paola De Lorenzo, The Lancet Hematological MalignancyAcute Lymphoblastic LeukaemiaOncologyPediatric EpidemiologyPediatric Hematology	2007	644
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia Jeffrey E. Rubnitz, Hiroto Inaba, Raul C. Ribeiro, Journal of Clinical Oncology Hematological MalignancyCell TherapyTransplantationMarrow TransplantationAcute Myeloid Leukemia	2010	638
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial Jeffrey E. Rubnitz, Hiroto Inaba, Gary V. Dahl, The Lancet Oncology Hematological MalignancyPediatric HematologyMedicineMixed-phenotype Acute LeukemiaHematology	2010	571
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Sheila Shurtleff, Arjan Buijs, F G Behm, PubMed	1995	561
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) Kirk R. Schultz, DJ Pullen, Harland N. Sather, Blood	2006	474
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Elaine Coustan‐Smith, José Sancho, Michael L. Hancock, Blood	2000	472
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital Ching‐Hon Pui, John T. Sandlund, Deqing Pei, Blood	2004	461
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Elaine Coustan‐Smith, Frederick G. Behm, Joaquín Sánchez, The Lancet Hematological MalignancyImmunological DetectionLymphoid NeoplasiaAcute Lymphoblastic LeukaemiaPediatric Hematology	1998	454

Page 1